GPP
TOVX icon

Great Point Partners’s Theriva Biologics TOVX Stock Holding History

Great Point Partners’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-457
Closed -$5.84M – 39
2014
Q4 		$5.84M Buy
+457
New +$6.14M 2.81% 13

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Great Point Partners's TOVX Position: Q1 2015 in Review

Great Point Partners sold out of Theriva Biologics (TOVX) in Q1 2015, closing a stake of 457 shares — an estimated $5.84M sold.

Great Point Partners first reported a position in TOVX in Q4 2014 and held it in 1 quarter. The position peaked at $5.84M in Q4 2014. 38 funds tracked by Wall St. Rank hold TOVX as of Q1 2015.

  • Great Point Partners reported no remaining Theriva Biologics position as of Q1 2015 after selling out during the quarter.
  • Great Point Partners sold 457 Theriva Biologics shares in Q1 2015, an estimated $5.84M.
  • Great Point Partners first reported a position in Theriva Biologics in Q4 2014 and held it in 1 quarter.
  • Great Point Partners's Theriva Biologics position peaked at $5.84M in Q4 2014.
  • 38 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2015.

Based on Great Point Partners's 13F filing for Q1 2015, filed 15 May 2015.